Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
about
Targeted therapies and immunotherapy in non-small-cell lung cancerUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceAfatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions.HER2 mutations in Chinese patients with non-small cell lung cancer.Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.The safety of afatinib for the treatment of non-small cell lung cancer.Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on AfatinibPredicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'.The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysisChange from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib.Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI.Role of afatinib in the treatment of advanced lung squamous cell carcinoma.Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations.Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study.Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer.Efficacy of icotinib in advanced lung squamous cell carcinomaA phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumorsLung cancer in never smokers-the East Asian experience
P2860
Q26738986-E01E66C2-8F32-49C1-8E95-32BB422D80D6Q28075291-82B2FD64-4D66-4B61-9A64-778B4A0941B9Q28079320-2207D4C0-7DA2-4C04-AC49-CC8E0CAEE4BDQ31160116-847738EE-A107-4C11-BF33-2D5F76820899Q33704088-7D05AB65-E28D-46B3-84A7-3FC3D495FD9AQ37637905-BCC45E25-DCEB-445A-88FE-F52C14F9EA39Q37702099-9FD5E6E8-C789-4BB6-829F-5956539D2D43Q37718501-741A32F2-158E-4E69-A79F-6E6CA4D7AC26Q38665706-9C9C7F9D-CF98-4147-9E6B-E9CB4E2AC9E3Q38682189-449A1232-2681-45B6-B1A5-2E84F8673D7BQ38955468-9FE2DCC9-3F13-486D-A50D-C4090581715EQ38990576-7414543F-0368-4AF2-B051-D57D2F25DF9DQ39007500-9ACF2C7E-E8A0-4CED-9B2D-3D7366575E41Q39131033-DC670714-D168-4FD0-9100-5AE78C0CD910Q39339545-93A68C49-B0A1-4A91-9ABE-B907DA376ABAQ40169633-85703328-DA06-43CD-A3FA-D3EBA7B0FDF1Q41242162-E835051B-B0C7-4878-B711-0AFC48F7D56BQ41709251-D72536F6-3A26-4A9B-889B-1ECB99FD4080Q42106824-6E641AF5-BC26-4050-B181-6000365A9FDAQ42362304-5D8A9884-D85C-4DFD-ADC0-DEF0A02840B4Q47093485-0EA5EC16-8152-4FD4-BA92-9C7CC2FE2C8AQ47107157-7AE5C586-5A1E-4544-BAA1-8BB94606E5EBQ47124054-CFA111F5-200B-421F-8D90-C35B8BCAB0CDQ47446113-C82F790A-CAA0-4CEA-A3C3-1AFC5A4D16ADQ48365834-5B857DE8-EE31-4573-BFCD-6B1D7C4AA782Q49300205-9C5AF939-8F90-4C88-842E-EA1F08F8DD42Q49720695-F595B8AE-C16A-4C0F-98BA-BC89DA554745Q52611428-00905964-AA74-4BFB-BE27-EE09191A7C6EQ54123036-66472881-698E-402D-91E9-D3D2ECC65E90Q55224621-D7104C99-D7E7-4D44-9732-3634E329082CQ58779811-98A3E80E-3AB9-437D-AEFC-1D5836E1CE3CQ58796519-B85517FB-E6BA-4BE0-A02C-0368A16C0C07Q58804388-0B562D18-8A09-4C2D-8293-C6EDC94D81E2
P2860
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Afatinib beyond progression in ...... I randomized LUX-Lung 5 trial.
@ast
Afatinib beyond progression in ...... I randomized LUX-Lung 5 trial.
@en
type
label
Afatinib beyond progression in ...... I randomized LUX-Lung 5 trial.
@ast
Afatinib beyond progression in ...... I randomized LUX-Lung 5 trial.
@en
prefLabel
Afatinib beyond progression in ...... I randomized LUX-Lung 5 trial.
@ast
Afatinib beyond progression in ...... I randomized LUX-Lung 5 trial.
@en
P2093
P2860
P356
P1433
P1476
Afatinib beyond progression in ...... I randomized LUX-Lung 5 trial.
@en
P2093
D Planchard
F De Marinis
J Bennouna
J C-H Yang
P2860
P304
P356
10.1093/ANNONC/MDV597
P577
2015-12-08T00:00:00Z